Suchergebnisse - "Dupilumab"

PubPharm (342)

1

Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis

enthalten in: The Journal of allergy and clinical immunology | 2024

von Clabbers, J. | Boesjes, C. | Spekhorst, L. | +11

2

Interleukin antagonists for atopic dermatitis : a new era of therapy

enthalten in: Expert opinion on investigational drugs | 2024

von Tsiogka, A. | Paschou, E. | Koumaki, D. | +2

3

Revolutionizing the management of patients with atopic dermatitis : practical considerations

enthalten in: Expert opinion on biological therapy | 2024

von Russo, F. | Giampetruzzi, A. | Pilla, M. | +2

4

Dupilumab therapy improves gut microbiome dysbiosis and tryptophan metabolism in Chinese patients with atopic dermatitis

enthalten in: International immunopharmacology | 2024

von Yang, L. | Li, D. | Sun, S. | +11

5

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

enthalten in: Dermatology and therapy | 2024

von Torres, T. | Sohrt Petersen, A. | Ivens, U. | +3

6

The association between expression of CD200 on B lymphocytes and the count of eosinophils and basophils in atopic dermatitis patients with and without dupilumab therapy - Pilot study

enthalten in: International immunopharmacology | 2024

von Čelakovská, J. | Čermákova, E. | Boudková, P. | +2

7

Dupilumab in patients with atopic dermatitis : assessing treatment response, clinical features and potential biomarkers in real-life

enthalten in: European annals of allergy and clinical immunology | 2024

von Limão, R. | Brás, R. | Pedro, E. | +2

8

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

enthalten in: Dermatology and therapy | 2024

von Torres, T. | Sohrt Petersen, A. | Ivens, U. | +3

9

Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'

enthalten in: Dermatology and therapy | 2024

von Bastian, M. | Freemantle, N. | Rossi, A. | +5

CommentOn: Dermatol Ther (Heidelb). 2024 Jan;14(1):169-182. - PMID 37897645

10

Learning from nemolizumab : A promising therapy for prurigo nodularis

enthalten in: The Journal of allergy and clinical immunology | 2024

von Kim, B.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[35]